Bausch + Lomb Co. (NYSE:BLCO) Shares Sold by Soleus Capital Management L.P.

Soleus Capital Management L.P. lowered its position in shares of Bausch + Lomb Co. (NYSE:BLCO - Free Report) by 61.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 120,500 shares of the company's stock after selling 191,500 shares during the quarter. Soleus Capital Management L.P.'s holdings in Bausch + Lomb were worth $2,176,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of BLCO. Tang Capital Management LLC raised its holdings in shares of Bausch + Lomb by 28.6% during the fourth quarter. Tang Capital Management LLC now owns 450,000 shares of the company's stock worth $8,127,000 after purchasing an additional 100,000 shares during the period. Polar Asset Management Partners Inc. grew its position in shares of Bausch + Lomb by 120.4% during the 4th quarter. Polar Asset Management Partners Inc. now owns 33,062 shares of the company's stock valued at $597,000 after buying an additional 18,062 shares during the last quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Bausch + Lomb by 34.5% in the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 52,460 shares of the company's stock worth $947,000 after acquiring an additional 13,460 shares during the last quarter. Millennium Management LLC bought a new position in Bausch + Lomb in the fourth quarter worth about $735,000. Finally, King Street Capital Management L.P. boosted its stake in Bausch + Lomb by 55.2% in the fourth quarter. King Street Capital Management L.P. now owns 1,136,321 shares of the company's stock valued at $20,522,000 after acquiring an additional 404,256 shares during the period. Institutional investors and hedge funds own 11.07% of the company's stock.

Bausch + Lomb Price Performance

Shares of NYSE:BLCO traded up $0.08 during trading on Thursday, reaching $11.27. The company had a trading volume of 540,344 shares, compared to its average volume of 667,187. The firm's fifty day moving average is $12.81 and its 200 day moving average is $16.11. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.01 and a current ratio of 1.60. The firm has a market capitalization of $3.98 billion, a PE ratio of -12.38, a price-to-earnings-growth ratio of 0.85 and a beta of 0.58. Bausch + Lomb Co. has a twelve month low of $10.45 and a twelve month high of $21.69.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last announced its earnings results on Wednesday, April 30th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.10). The firm had revenue of $1.15 billion for the quarter, compared to the consensus estimate of $1.15 billion. Bausch + Lomb had a positive return on equity of 3.35% and a negative net margin of 6.62%. Bausch + Lomb's revenue for the quarter was up 3.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.07 EPS. On average, equities analysts forecast that Bausch + Lomb Co. will post 0.74 EPS for the current year.

Analysts Set New Price Targets

BLCO has been the subject of a number of recent research reports. Morgan Stanley lowered their price objective on Bausch + Lomb from $18.00 to $12.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. Needham & Company LLC restated a "hold" rating on shares of Bausch + Lomb in a research report on Thursday, April 24th. Royal Bank of Canada dropped their price objective on shares of Bausch + Lomb from $18.00 to $17.00 and set an "outperform" rating on the stock in a report on Friday, April 4th. Bank of America reduced their target price on shares of Bausch + Lomb from $18.00 to $17.00 and set an "underperform" rating for the company in a research note on Thursday, February 20th. Finally, Wells Fargo & Company dropped their price target on shares of Bausch + Lomb from $15.00 to $12.00 and set an "equal weight" rating on the stock in a research note on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $15.50.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.